Yes, it sure appears as boiler room jazz on his part. A field day for him.
But,as much of a believer as i have been for years,and remain so in the science and lanza,it takes so much more for a developing biotech to survive. History of developing biotechs is replete with financial disasters and bankruptcies. And let's not over inflate the importance of phase 1 as the end all and be all,because it isn't anywhere enough data period.
There's so much promise apparently, I still believe the company's science will prevail in a new form, under eventual new owners and we the retail shareholders will be screwed, to put it bluntly. We are the far least important cog in their business plan and if they can dramatically mitigate/reduce all the new debt about to hit them, wouldn't any rational person believe they are in deep trouble and will reorganize? To go the more dilution route after all that has transpired already makes our money in this investment silly to very questionable it sure seems. It hurts.
As stated before, would love a board poster experienced in corporate finance management, if su h exists, to share candid,honest thoughts with us.
Until midnite tonite, it seems the company has not been totally transparent re: their default, which my understanding is a serious SEC violation and i have no interest in the stock being halted and my investment frozen, if that should happen.
Market Data 
Markets 
AI
